Stockreport

Global Dyskinesia Pipeline Insight 2024: In-depth Analysis on Emerging Drugs, Companies, and Ongoing Clinical Trials [Yahoo! Finance]

SUMITOMO CHEM UNSP/ADR  (SOMMY) 
NASDAQ:AMEX Investor Relations: sumitomo-chem.co.jp/english/ir
PDF The global healthcare industry witnesses a pivotal development in the domain of neurological disorder treatment, as an extensive "Dyskinesia- Pipeline Insight, 2024" re [Read more]